4
Participants
Start Date
September 3, 2021
Primary Completion Date
December 17, 2024
Study Completion Date
June 18, 2029
VTX-801
"The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels."
Aarhus University Hospital, Aarhus
Wake Forest School of Medicine, Winston-Salem
Advent Health, Orlando
University Hospital Essen, Essen
University of Michigan Health System, Ann Arbor
Universitätsklinikum Tübingen (UKT), Tübingen
University of Texas Southwestern Medical Center, Dallas
UC Davis Medical Center, Sacramento
Yale University School of Medecine, New Haven
Royal Surrey County Hospital, Guildford
Vivet Therapeutics SAS
INDUSTRY